Practical aspects in the management of vaginal atrophy and sexual dysfunction in perimenopausal and postmenopausal women

Journal of Sexual Medicine

Volumn 2, Issue SUPPL. 3, 2005, Pages 154-165

  Goldstein, Irwin ^a   Alexander, Jeanne Leventhal ^b  

^a Kaiser Permanente ^*  (United States)

^b KAISER PERMANENTE   (United States)

Author keywords

Management; Postmenopause; Sexual Dysfunction; Vaginal Atrophy

Indexed keywords

ANDROGEN; ESTRADIOL; ESTROGEN; ESTRONE; FOLLITROPIN; LUTEINIZING HORMONE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PRASTERONE; PROGESTERONE; PROLACTIN; PROSTAGLANDIN E1; TESTOSTERONE; THYROTROPIN; TIBOLONE;

ANAMNESIS; CLINICAL TRIAL; FOLLOW UP; HAIR DISEASE; HORMONAL REGULATION; HORMONAL THERAPY; HUMAN; LABORATORY TEST; LARYNX DISORDER; MEDICAL LITERATURE; PATIENT EDUCATION; PH; PHYSICAL EXAMINATION; POSTMENOPAUSE; PRESCRIPTION; PRIORITY JOURNAL; SEXUAL AROUSAL; SEXUAL DYSFUNCTION; SHORT SURVEY; SIDE EFFECT; SMOOTH MUSCLE RELAXATION; VAGINA ATROPHY; WEIGHT GAIN;

EID: 28444457671     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2005.00131.x     Document Type: Article

References (47)

1. Freedman MA. Quality of life and menopause: The role of estrogen. J Womens Health (Larchmt) 2002;11:703-18.
2. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: Prevalence and predictors. JAMA 1999;281:537-44.
3. Dennerstein L, Randolph J, Taffe J, Dudley E, Burger H. Hormones, mood, sexuality, and the menopausal transition. Fertil Steril 2002;77(suppl 4):S42-S48.
4. Lewis RW, Fugl-Meyer KS, Bosch R, Fugl-Meyer AR, Laumann EO, Lizza E, Martin-Morales A. Epidemiology/risk factors of sexual dysfunction. J Sex Med 2004;1:35-9.
5. Hatzichristou D, Rosen RC, Broderick G, Clayton A, Cuzin B, Derogatis L, Litwin M, Meuleman E, O'Leary M, Quirk F, Sadovsky R, Seftel A. Clinical evaluation and management strategy for sexual dysfunction in men and women. J Sex Med 2004;1:49-57.
6. Davis SR, Guay AT, Shifren JL, Mazer NA. Endocrine aspects of female sexual dysfunction. J Sex Med 2004;1:82-6.
7. Nappi R, Salonia A, Traish AM, van Lunsen RHW, Vardi Y, Kodiglu A, Goldstein I. Clinical biologic pathophysiologies of women's sexual dysfunction. J Sex Med 2005;2:4-25.
8. Hayes R, Dennerstein L. The impact of aging on sexual function and sexual dysfunction in women: A review of population based studies. J Sex Med 2005;2:317-30.
9. Basson R, Althof S, Davis S, Fugl-Meyer KS, Goldstein I, Leiblum S, Meston C, Rosen R, Wagner G. Summary of the recommendations on sexual dysfunctions in women. J Sex Med 2004;1:24-35.
10. Basson R, Brotto LA, Laan E, Redmond C, Utian WH. Assessment and management of women's sexual dysfunctions: Problematic desire and arousal. J Sex Med 2005;2:291-300.
11. Riley A. The role of the partner in erectile dysfunction and its treatment. Int J Impot Res 2002;14(suppl 1):S105-S109.
12. Johnston SL, Farrell SA, Bouchard C, Farrell SA, Beckerson LA, Comeau M, Johnston SL, Lefebvre G, Papaioannou A, SOGC Joint Committee-Clinical Practice Gynaecology and Urogynaecology. The detection and management of vaginal atrophy. Obstet Gynaecol Can 2004;26:503-15.
13. Palacios S, Castelo-Branco C, Cancelo MJ, Vazquez F. Low-dose, vaginally administered estrogens may enhance local benefits of systemic therapy in the treatment of urogenital atrophy in postmenopausal women on hormone therapy. Maturitas 2005;50:98-104.
14. Giraldi A, Marson L, Nappi R, Pfaus J, Traish AM, Vardi Y, Goldstein I. Physiology of female sexual function: Animal models. J Sex Med 2004;1:237-53.
15. Graziottin A, Leiblum S. Biological and psychosocial pathophysiology of female sexual dysfunction during the menopausal transition. J Sex Med 2005;2(suppl 3):133-45.
16. Utian WH, Shoupe D, Bachmann G, Pinkerton JV, Pickar JH. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001;75:1065-79.
17. Barentsen R, van de Weijer PH, Schram JH. Continuous low dose estradiol released from a vaginal ring versus estriol vaginal cream for urogenital atrophy. Eur J Obstet Gynecol Reprod Biol 1997;71:73-80.
18. Marx P, Schade G, Wilbourn S, Blank S, Mover DL, Nett R. Low-dose (0.3 mg) synthetic conjugated estrogens A is effective for managing atrophic vaginitis. Maturitas 2004;47:47-54.
19. Dennerstein L, Lehert P, Burger H. The relative effects of hormones and relationship factors on sexual functioning of women through the natural menopausal transition. Fertil Steril 2005;84:174-80.
20. Kovalevsky G. Hormones & female sexual dysfunction in postmenopausal women. Menopausal Med 2004;12:1-5.
21. Erol B, Tefekli A, Sanli O, Ziylan O, Armagan A, Kendirci M, Eryasar D, Kadioglu A. Does sexual dysfunction correlate with deterioration of somatic sensory system in diabetic women? Int J Impot Res 2003;15:198-202.
22. Sarrel PM. Effects of hormone replacement therapy on sexual psychophysiology and behavior in postmenopause. J Womens Health Gend Based Med 2000;9(suppl 1):S25-S32;
23. published erratum: J Womens Health Gend Based Med 2001;10:91.
24. Alexander JL, Kotz K, Dennerstein L, Kutner SJ, Wallen K, Notelovitz M. The effects of postmenopausal hormone therapies on female sexual functioning: A review of double-blind, randomized controlled trials. Menopause 2004;11(6 Part 2):749-65.
25. Buster JE, Kingsberg SA, Aguirre O, Brown C, Breaux JG, Buch A, Rodenberg CA, Wekselman K, Casson P. Testosterone patch for low sexual desire in surgically menopausal women: A randomized trial. Obstet Gynecol 2005;105:944-52.
26. Razvi S, Ingoe LE, McMillan CV, Weaver JU. Health status in patients with sub-clinical hypothyroidism. Eur J Endocrinol 2005;152:713-7.
27. Harrison WM, Rabkin JG, Ehrhardt AA, Stewart JW, McGrath PJ, Ross D, Quitkin FM. Effects of antidepressant medication on sexual function: A controlled study. J Clin Psychopharmacol 1986;6:144-9.
28. Montejo AL, Llorca G, Izguierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: A prospective multicenter study of 1,022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry 2001;62(suppl 3):10-21.
29. Clayton AH, Pradko JF, Croft HA, Montano CB, Leadbetter RA, Bolden-Watson C, Bass KI, Donahue RM, Jamerson BD, Metz A. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 2002;63:357-66.
30. Model JG, Katholi CR, Modell JD, DePalma L. Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline. Clin Pharmacol Ther 1997;61:476-87.
31. Greden JF. The burden of disease for treatment-resistant depression. J Clin Psychiatry 2001;62(suppl 16):26-31.
32. Fava M, Amsterdam JD, Deltito JA, Salzman C, Schwaller M, Dunner DL. A double-blind study of paroxetine, fluoxetine, and placebo in outpatients with major depression. Ann Clin Psychiatry 1998; 10:145-50.
33. Labbate LA, Grimes J, Hines A, Oleshansky MA, Arana GW. Sexual dysfunction induced by serotonin reuptake antidepressants. J Sex Marital Ther 1998;24:3-12.
34. Ekselius L, von Knorring L. Effect of sexual function of long term treatment with selective serotonin reuptake inhibitors in depressed patients treated in primary care. J Clin Psychopharmacol 2001;21:154-60.
35. Nurnberg HG, Hensley PL, Gelenberg AJ, Fava M, Lauriello J, Paine S. Treatment of antidepressant-associated sexual dysfunction with sildenafil: A randomized controlled trial. JAMA 2003;289:56-64.
36. Nurnberg HG, Hensley PL. Selective phosphodiesterase type-5 inhibitor treatment of serotonergic reuptake inhibitor antidepressant-associated sexual dysfunction: A review of diagnosis, treatment, and relevance. CNS Spectr 2003;8:194-202.
37. Nurnberg HG. Managing treatment-emergent sexual dysfunction associated with serotonergic antidepressants: Before and after sildenafil. J Psychiatr Pract 2001;7:92-108.
38. Na N. Recommendations for estrogen and progestogen use in peri-and postmenopausal women: October 2004 position statement of The North American Menopause Society. Menopause 2004;11:589-600.
39. Bachmann GA, Leiblum SR. The impact of hormones on menopausal sexuality: A literature review. Menopause 2004;11:120-30.
40. Cutler WB, Garcia CR, McCoy N. Perimenopausal sexuality. Arch Sex Behav 1987;16:225-34.
41. Willhite LA, O'Connell MB. Urogenital atrophy: Prevention and treatment. Pharmacotherapy 2001;21:464-80.
42. Ayton RA, Darling GM, Murkies AL, Farrell EA, Weisberg E, Selinus I, Eraser ID. A comparative study of safety and efficacy of continuous low dose oestradiol released from a vaginal ring compared with conjugated equine oestrogen vaginal cream in the treatment of postmenopausal urogenital atrophy. Br J Obstet Gynaecol 1996;103:351-8.
43. Rioux JE, Devlin C, Gelfand MM, Steinberg WM, Hepburn DS. 17beta-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause 2000;7:156-61.
44. Dennerstein L, Burrows GD, Wood C, Hyman G. Hormones and sexuality: Effect of estrogen and progestogen. Obstet Gynecol 1980;56:316-22.
45. Barnhart KT, Freeman E, Grisso JA, Rader DJ, Sammel M, Kapoor S, Nestler JE. The effect of dehydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health-related quality of life. J Clin Endocrinol Metab 1999;84:3896-902.
46. Shifren JL, Braunstein GD, Simon JA, Casson PR, Buster JE, Redmond GP, Burki RE, Ginsburg ES, Rosen RC, Leiblum SR, Caramelli KE, Mazer NA. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 2000;343:682-8.
47. Davis SR. The effects of tibolone on mood and libido. Menopause 2002;9:162-70.